Neoantigens are recently developed antigens that have not been detected by the immune system historically. Alterations in tumor proteins may result in the development of neoantigens caused by mutations or viral proteins. Neoantigens are used in selective treatments for cancerous cells.
The neoantigens market is segmented based on treatment, therapeutic specialty, and geography. Based on geography, the market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis of the neoantigens market emphasizing on various parameters such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players across the world. It also includes COVID-19 impact analysis across all the regions. It is estimated that the market is likely to have a steady growth rate during the forecast period.
You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities
Neoantigens Market: Strategic Insights
Developments in biotechnology have led to rise in acceptance for immunotherapy, further driving its use in personalized medicines. Immunotherapy is widely used to treat cancer; a few the immunotherapy procedures involve the use of neoantigens, the antigens present on the surface of cancer cells. Therefore, applications of neoantigens are being widely studied to treat cancer. The uniqueness of neoantigens allows researchers to identify patients’ immune system and find antigens to target cancer cells without disturbing healthy cells.
The developments in immunotherapy caught pace after 2015, when the first clinical trial of neoantigen vaccine was performed. In 2017, two additional clinical trial studies were published by Neon Therapeutics that proved the efficacy of neoantigen vaccine treat melanoma (skin cancer) in humans. The positive results of clinical trials have attracted various startups to discover and develop neoantigen-based cancer therapeutics. Many companies have shown interest in the development of neoantigens. Following are few examples of companies involved in the development of neoantigens.
Such developments in the neoantigen vaccines against cancer are fuelling the market growth.
Based on treatment, the neoantigens market is segmented into combination therapy and mono therapy. In 2023, the combination therapy segment is estimated to have a larger share of the market. However, the mono therapy segment is expected to have a faster growth during the forecast period.
Based on therapeutic specialty, the neoantigens market is segmented into gastrointestinal cancer, lung cancer, solid tumor, urinary systems cancers, melanoma, head and neck cancer, and others. In 2023, the gastrointestinal cancer segment is estimated to hold the largest share of the market and is expected to grow at the fastest rate in the coming years.
Inorganic strategies were highly adopted by the market players to meet the changing customer demand and maintain their improved services. For instance, in January 2021, Genocea Announces Cancer Discovery Publication owing to the benefits of neoantigen identification using the ATLAS Platform. This discovery strengthens neoantigen immunotherapies by theoretically ensuring that they target the correct neoantigens while removing Inhibigens.
The regional trends and factors influencing the Neoantigens Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Neoantigens Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 271.43 Million |
| Market Size by 2028 | US$ 1,054.78 Million |
| Global CAGR (2023 - 2028) | 31.2% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2028 |
| Segments Covered |
By Treatment
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Neoantigens Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Neoantigens Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The List of Companies - Neoantigens Market
Several companies into clinical trial phases for their respective neoantigens. It is expected that by 2023, companies will commercialize their products in the market. In addition, it is expected that the cost of neoantigens will be much higher than cancer vaccines.
Key factors that are driving growth of the market are developments in neoantigen vaccines against cancer and increasing prevalence of cancer. However, possible side effects associated with neoantigen vaccines are likely to hinder the growth of the neoantigens market.
Neoantigens are recently developed antigens that have not been detected by the immune system historically. Alterations in tumor proteins may result in the development of neoantigens caused by mutations or viral proteins. Neoantigens are used in selective treatments for cancerous cells.